Subscribe to our Newsletters !!
Anemones Sea have a striking beauty and the abilit
Today, we live in a world of advanced biotechnolog
A new COVID-19 variant, BA.3.2, informally called
Alembic Pharmaceutica
Potassium cyanide is infamous in the world for the
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-look
New Delhi: Drug major Aurobindo Pharma on Friday said it has received final approval from the US health regulator to manufacture and market Droxidopa capsules, used to treat dizziness and lightheadedness. The approved product is a generic version of Lundbeck NA Ltd’s Northera capsules.
The business has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Droxidopa capsules at the advantages of 100 mg, 200 mg and 300 mg, Aurobindo Pharma stated in a regulatory filing.
The company said the product will be launched immediately.
Droxidopa is approved for the treatment of orthostatic dizziness and lightheadedness in adult patients with symptomatic neurogenic orthostatic hypotension (low blood pressure).
Quoting IQVIA data, Aurobindo Pharma said the approved product has an estimated market size of USD 352 million for the twelve months ending December 2020.
Aurobindo now has a total of 469 abbreviated new drug application (ANDA) approvals (440 closing and 29 tentative) from USFDA.
Shares of Aurobindo Pharma were trading 1.21 percent lower at Rs 901.60 apiece on BSE.
